155 related articles for article (PubMed ID: 18441772)
1. Efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris in adolescents.
Raimer S; Maloney JM; Bourcier M; Wilson D; Papp K; Siegfried E; Garrett S;
Cutis; 2008 Feb; 81(2):171-8. PubMed ID: 18441772
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and tolerability of dapsone 5% gel in female vs male patients with facial acne vulgaris: gender as a clinically relevant outcome variable.
Tanghetti E; Harper JC; Oefelein MG
J Drugs Dermatol; 2012 Dec; 11(12):1417-21. PubMed ID: 23377510
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: Second of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-Controlled Trials.
Eichenfield LF; Lain T; Frankel EH; Jones TM; Chang-Lin JE; Berk DR; Ruan S; Kaoukhov A
J Drugs Dermatol; 2016 Aug; 15(8):962-9. PubMed ID: 27537997
[TBL] [Abstract][Full Text] [Related]
4. Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment.
Lucky AW; Maloney JM; Roberts J; Taylor S; Jones T; Ling M; Garrett S;
J Drugs Dermatol; 2007 Oct; 6(10):981-7. PubMed ID: 17966175
[TBL] [Abstract][Full Text] [Related]
5. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris.
Draelos ZD; Carter E; Maloney JM; Elewski B; Poulin Y; Lynde C; Garrett S;
J Am Acad Dermatol; 2007 Mar; 56(3):439.e1-10. PubMed ID: 17208334
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: First of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-controlled Trials.
Stein Gold LF; Jarratt MT; Bucko AD; Grekin SK; Berlin JM; Bukhalo M; Weiss JS; Berk DR; Chang-Lin JE; Lin V; Kaoukhov A
J Drugs Dermatol; 2016 May; 15(5):553-61. PubMed ID: 27168264
[TBL] [Abstract][Full Text] [Related]
7. Treatment Response With Once-Daily Topical Dapsone Gel, 7.5% for Acne Vulgaris: Subgroup Analysis of Pooled Data from Two Randomized, Double-Blind Stu.
Draelos ZD; Rodriguez DA; Kempers SE; Bruce S; Peredo MI; Downie J; Chang-Lin JE; Berk DR; Ruan S; Kaoukhov A
J Drugs Dermatol; 2017 Jun; 16(6):591-598. PubMed ID: 28686777
[TBL] [Abstract][Full Text] [Related]
8. Dapsone 5% gel: a review of its efficacy and safety in the treatment of acne vulgaris.
Stotland M; Shalita AR; Kissling RF
Am J Clin Dermatol; 2009; 10(4):221-7. PubMed ID: 19489655
[TBL] [Abstract][Full Text] [Related]
9. Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris.
Tanghetti E; Dhawan S; Green L; Ling M; Downie J; Germain MA; Kasteler JS; Kircik L; Oefelein MG; Draelos Z
J Drugs Dermatol; 2011 Jul; 10(7):783-92. PubMed ID: 21720661
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of clindamycin phosphate 1.2%-benzoyl peroxide 3% fixed-dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double-blind, active- and vehicle-controlled study.
Eichenfield LF; Alió Sáenz AB
J Drugs Dermatol; 2011 Dec; 10(12):1382-96. PubMed ID: 22134562
[TBL] [Abstract][Full Text] [Related]
11. Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12-week, randomized, double-blind study.
Fleischer AB; Shalita A; Eichenfield LF; Abramovits W; Lucky A; Garrett S;
J Drugs Dermatol; 2010 Jan; 9(1):33-40. PubMed ID: 20120423
[TBL] [Abstract][Full Text] [Related]
12. Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris.
Piette WW; Taylor S; Pariser D; Jarratt M; Sheth P; Wilson D
Arch Dermatol; 2008 Dec; 144(12):1564-70. PubMed ID: 19075138
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, Safety, and Tolerability of Topical Dapsone Gel, 7.5% for Treatment of Acne Vulgaris by Fitzpatrick Skin Phototype.
Taylor SC; Cook-Bolden FE; McMichael A; Downie JB; Rodriguez DA; Alexis AF; Callender VD; Alvandi N
J Drugs Dermatol; 2018 Feb; 17(2):160-167. PubMed ID: 29462223
[TBL] [Abstract][Full Text] [Related]
14. Cohort study on the treatment with dapsone 5% gel of mild to moderate inflammatory acne of the face in women.
Lynde CW; Andriessen A
Skinmed; 2014; 12(1):15-21. PubMed ID: 24720080
[TBL] [Abstract][Full Text] [Related]
15. A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne.
Gold LS; Tan J; Cruz-Santana A; Papp K; Poulin Y; Schlessinger J; Gidner J; Liu Y; Graeber M;
Cutis; 2009 Aug; 84(2):110-6. PubMed ID: 19746769
[TBL] [Abstract][Full Text] [Related]
16. Use of Dapsone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Dapsone 5% Gel Combination Treatment.
Kircik LH
J Drugs Dermatol; 2016 Feb; 15(2):191-5. PubMed ID: 26885787
[TBL] [Abstract][Full Text] [Related]
17. Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females.
Tanghetti E; Harper J; Baldwin H; Kircik L; Bai Z; Alvandi N
J Drugs Dermatol; 2018 Nov; 17(11):1192-1198. PubMed ID: 30500139
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris.
Thiboutot DM; Willmer J; Sharata H; Halder R; Garrett S
Clin Pharmacokinet; 2007; 46(8):697-712. PubMed ID: 17655376
[TBL] [Abstract][Full Text] [Related]
19. Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females.
Tanghetti E; Harper J; Baldwin H; Kircik L; Bai Z; Alvandi N
J Drugs Dermatol; 2018 Nov; 17(11):1192-1198. PubMed ID: 30500141
[TBL] [Abstract][Full Text] [Related]
20. Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females.
Tanghetti E; Harper J; Baldwin H; Kircik L; Bai Z; Alvandi N
J Drugs Dermatol; 2018 Nov; 17(11):1192-1198. PubMed ID: 30500140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
